TWSTTwist Bioscience Corp

Nasdaq twistbioscience.com


$ 49.99 $ -0.45 (-0.89 %)    

Monday, 10-Jun-2024 15:59:50 EDT
QQQ $ 464.61 $ 1.87 (0.4 %)
DIA $ 389.34 $ 0.80 (0.21 %)
SPY $ 535.72 $ 1.65 (0.31 %)
TLT $ 90.89 $ -0.61 (-0.67 %)
GLD $ 213.56 $ 1.94 (0.92 %)
$ 50.01
$ 49.24
$ 0.00 x 0
$ 0.00 x 0
$ 48.23 - $ 50.49
$ 14.42 - $ 54.13
969,826
na
2.89B
$ 1.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-02-2024 12-31-2023 10-Q
3 11-21-2023 09-30-2023 10-K
4 08-07-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-07-2023 12-31-2022 10-Q
7 11-28-2022 09-30-2022 10-K
8 08-08-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-Q
11 11-23-2021 09-30-2021 10-K
12 08-09-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 02-09-2021 12-31-2020 10-Q
15 11-27-2020 09-30-2020 10-K
16 08-12-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 02-10-2020 12-31-2019 10-Q
19 12-13-2019 09-30-2019 10-K
20 08-09-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-11-2019 12-31-2018 10-Q
23 12-20-2018 09-30-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

 twist-bioscience-preclinical-data-detailing-discovery-of-antibody-targeting-emerging-checkpoint-inhibitor-published-in-the-journal-plos-one

TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing acti...

 guggenheim-initiates-coverage-on-twist-bioscience-with-buy-rating-announces-price-target-of-53

Guggenheim analyst Subbu Nambi initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Buy rating and announces Price Ta...

 twist-bioscience-launches-multiplexed-gene-fragments-pools-of-directly-synthesized-double-stranded-dna-up-to-500-base-pairs-in-length-with-no-limit-on-sequence-number-to-enable-high-throughput-screening-applications

No limit to number of fragments included in the poolsOptimized chemistry enables direct synthesis of up to 500 bp double strand...

 cathie-woods-ark-invest-purchases-over-30m-of-shopify-shares-amid-q1-numbers-driven-plunge-adds-reddit-shares-to-kitty--offloads-coinbase-stock-as-bitcoin-declines

On Wednesday, Cathie Wood’s Ark Invest made some significant trades.

 cathie-woods-ark-invest-swoops-in-to-buy-the-palantir-dip--purchases-stock-worth-29m--offloads-coinbase-shares-worth-over-15m-amid-softening-bitcoin-price

On Tuesday, the Cathie Wood-led Ark Invest made some significant trades.

 scotiabank-maintains-sector-outperform-on-twist-bioscience-raises-price-target-to-48

Scotiabank analyst Sung Ji Nam maintains Twist Bioscience (NASDAQ:TWST) with a Sector Outperform and raises the price target...

 genomics-firm-twist-biosciences-momentum-to-continue-throughout-2024-analyst-says

Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands...

 evercore-isi-group-maintains-outperform-on-twist-bioscience-raises-price-target-to-50

Evercore ISI Group analyst Vijay Kumar maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price targe...

 barclays-maintains-overweight-on-twist-bioscience-raises-price-target-to-45

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $4...

 baird-maintains-outperform-on-twist-bioscience-raises-price-target-to-40

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $...

 twist-bioscience-raises-fy24-total-revenue-from-288m-293m-to-300m-304m-est-293085m

Ending cash, cash equivalents and short-term investments at September 30, 2024 of more than $245 million.